(Q37314847)

19 August 2017

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study (English)

1 reference

19 August 2017

0 references

1 reference

1

Ali Taher

1 reference

19 August 2017

Amal El-Beshlawy

2

1 reference

19 August 2017

Mohsen S Elalfy

3

1 reference

19 August 2017

Kusai Al Zir

4

1 reference

19 August 2017

Shahina Daar

5

1 reference

19 August 2017

Dany Habr

6

1 reference

19 August 2017

Ulrike Kriemler-Krahn

7

1 reference

19 August 2017

Abdel Hmissi

8

1 reference

19 August 2017

Abdullah Al Jefri

9

1 reference

19 August 2017

language of work or name

1 reference

28 January 2009

1 reference

European Journal of Haematology

19 August 2017

1 reference

19 August 2017

82

1 reference

19 August 2017

6

1 reference

19 August 2017

458-465

1 reference

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Growth of children with beta-thalassemia major

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

CDC growth charts: United States

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

6 September 2017

The beta-thalassemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Classification and diagnosis of iron overload

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Iron-chelating therapy and the treatment of thalassemia.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Histological grading and staging of chronic hepatitis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Results of long-term iron-chelating therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Complications of beta-thalassemia major in North America

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2730551

Survival in medically treated patients with homozygous beta-thalassemia

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19187278

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19187278

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19187278

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1600-0609.2009.01228.X

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19187278

1 reference